Summary
The Europe Gastrointestinal Therapeutics Market would witness market growth of 3.2% CAGR during the forecast period (2022-2028).
Most gastrointestinal drugs are designed to act locally, reducing systemic absorption as much as possible. When a prescription is absorbed systemically at low levels, informative pharmacokinetic and pharmacodynamic (PK/PD) drug profiles are difficult to obtain and usually require simulation and modeling. High-quality PK analysis is critical for making substantive arguments regarding the exposure-response relationship.
The gastrointestinal (GI) tract is a 25-foot-long pathway that extends from the anus to the mouth. Everything one eats passes through the esophagus and gets processed in the small intestine and the stomach to absorb nutrients. Finally, the waste is removed from the body through the colon and rectum. Sometimes a tumor can form in one of these organs due to the change in the DNA that causes abnormal cells to grow.
According to the UK National Screening Committee, stomach cancer tends to affect people aged 55 and above. It was seen as more common in men than in women. Presently bacterial infection causes around 40% of stomach cancers. It was found that people under 50 are developing stomach cancer due to various other factors, such as being obese. The burden of gastrointestinal and liver disease is heavy for patients. The NHS, and the economy, stated the gastrointestinal illness as the third most common cause of death, the leading cause of cancer death, and the most common reason of admission in hospitals.
The Germany market dominated the Europe Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,924.4 million by 2028. The UK market is anticipated to grow at a CAGR of 2.3% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 3.9% during (2022 - 2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn’s Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Scope of the Study
Market Segments covered in the Report:
By Type
• Branded
• Generics
By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Route of Administration
• Injectable
• Oral & Others
By Application
• Crohn’s Disease
• Ulcerative Colitis
• GERD
• IBS
• Others
By Drug Class
• Biologics/Biosimilar
• Anti-Diarrheal
• Anti-Emetics
• Digestive Enzymes
• Aminosalicylates
• Proton Pump Inhibitors
• Laxatives & H2 Antagonists
• Others
By Country
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
Companies Profiled
• Abbott Laboratories
• AbbVie, Inc.
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
• Johnson & Johnson (Janssen Global Services, LLC)
• AstraZeneca PLC
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
Unique Offerings
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
